Prof. Shu Xia 夏曙
Chief Physician, Professor
Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis, comprehensive treatment, and precise radiotherapy for malignant tumors including lung, esophageal, gastric, colorectal, and breast cancer.
Dr. Xia earned a medical doctorate from Tongji Medical University in 1997. A professor and chief physician, Dr. Xia spent nearly two years at the University of Wisconsin School of Medicine and Public Health’s Cancer Center and Translational Research Center. Dr. Xia has published over 20 papers and led research projects funded by the Ministry of Education, Hubei Province, and the Wu Jieping Foundation.
Professional roles
- Member, Lung Cancer Professional Committee, Hubei Anti-Cancer Association
- Member, Liver Cancer Professional Committee, Hubei Anti-Cancer Association
Name order: in Chinese the family name comes first (Xia Shu). Papers usually list the name as Shu Xia or Xia S.
Selected publications
43 papers on PubMed matched by name and affiliation; 17 as first or senior author since 2016. Most recent first- or senior-author papers:
- Biochem Pharmacol, 2026 (senior author): How diverse therapeutic strategies reshape the tumor immune microenvironment in small cell lung cancer: from radiation to engineered immunotherapies. PubMed 42556480
- Int Immunopharmacol, 2026 (senior author): PARP inhibitor combined with platinum activates the cGAS-STING pathway to enhance anti-PD-L1 immunotherapy in lung adenocarcinoma. PubMed 41650888
- Cancer Cell Int, 2026 (senior author): Correction: Annexin A1 promotes the progression of bladder cancer via regulating EGFR signaling pathway. PubMed 41792713
- Curr Oncol, 2026 (senior author): Deep Learning-Derived Pathomic Features Predict NCIT Efficacy in Resectable Locally Advanced ESCC: Clinical Utility and Mechanistic Insights. PubMed 41892164
- Biomolecules, 2025 (senior author): SIRT6 in Cancer: Mechanistic Insights into Its Dual Roles in Cancer Biology and Implications for Precision Therapeutic Development. PubMed 41463311
- Biochim Biophys Acta Mol Basis Dis, 2025 (senior author): ANXA1 facilitates myeloid-derived suppressor cell infiltration in the non-small cell lung cancer immunomicroenvironment via the STING/NF-κB/CXCL5/CXCR2 signaling axis to enhance tumor progression. PubMed 40617338
- Cancer Immunol Immunother, 2024 (senior author): Efficacy and safety of perioperative immunotherapy combinations for resectable non-small cell lung cancer: a systematic review and network meta-analysis. PubMed 39382658
- Int J Mol Sci, 2024 (senior author): Unveiling the Role of HGF/c-Met Signaling in Non-Small Cell Lung Cancer Tumor Microenvironment. PubMed 39201787
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion